Intensity of warfarin coagulation in the antiphospholipid syndrome

被引：8
作者：
Crowther M.A. [1 ]
机构：
[1] Division of Hematology and Thromboembolism, McMaster University, St Joseph's Hospital, 50 Charlton Ave, East Hamilton, ON
来源：
Current Rheumatology Reports | 2010年 / 12卷 / 1期
关键词：
Anticoagulation; Antiphospholipid syndrome; Lupus anticoagulant; Warfarin;
D O I：
10.1007/s11926-009-0070-9
中图分类号：
学科分类号：
摘要：
Antiphospholipid syndrome is a condition with an increased propensity for both arterial and venous thrombosis. Compared with the normal population there is also a higher rate of recurrence. Most evidence exists for the use of warfarin in the secondary prevention of thromboembolism, aiming for an international normalized ratio between 2.0 and 3.0. Care must be taken with all anticoagulants because of the increased risk of bleeding. Several other strategies are available if warfarin fails, including the addition of aspirin, increasing the warfarin target range, and use of heparin. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码：64 / 69
页数：5
相关论文
共 27 条
  • [1] Rosove M.H., Brewer P.M., Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients, Ann Intern Med, 117, pp. 303-308, (1992)
  • [2] Miyakis S., Lockshin M.D., Atsumi T., Et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, pp. 295-306, (2006)
  • [3] Conley C.L., Hartmann R.C., A haemorrhage disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus, J Lab Clin Invest, 31, pp. 621-622, (1952)
  • [4] Giannakopoulos B., Passam F., Rahgozar S., Krilis S.A., Current concepts on the pathogenesis of the antiphospholipid syndrome, Blood, 109, 2, pp. 422-430, (2007)
  • [5] Shi W., Krilis S.A., Chong B.H., Et al., Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population, Aust NZ J Med, 20, pp. 231-236, (1990)
  • [6] Vila P., Hernandez M.C., Lopez-Fernandez M.F., Batlle J., Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects, Thromb Haemost, 72, pp. 209-213, (1994)
  • [7] Galli M., Luciani D., Bertolini G., Barbui T., Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature, Blood, 101, 5, pp. 1827-1832, (2003)
  • [8] Janardhan V., Wolf P.A., Kase C.S., Massaro J.M., D'Agostino R.B., Franzblau C., Wilson P.W.F., Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: The framingham cohort and offspring study, Stroke, 35, 3, pp. 736-741, (2004)
  • [9] Erkan D., Harrison M.J., Levy R., Peterson M., Petri M., Sammaritano L., Unalp-Arida A., Vilela V., Yazici Y., Lockshin M.D., Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals, Arthritis and Rheumatism, 56, 7, pp. 2382-2391, (2007)
  • [10] Ruffatti A., Del Ross T., Ciprian M., Et al., Risk factors for a first thrombotic event in antiphospholipid antibody carriers: A multicentre, retrospective follow-up study, Ann Rheum Dis, 68, pp. 397-399, (2009)
123